Glaukos Corp (NYSE:GKOS)
March 21st, 2019
Amidst rising markets Glaukos Corp rose $3.03 Thursday, a 3.91% increase, closing at $80.54. Furthermore it hit a new 52 week high of $82.24. The stock continues to trade well at 201.08% of its 52 week low of $26.75.
Forecasts from 8 analysts suggest that Glaukos Corp might go down somewhat (-10.29%), while Finbox has calculated (with high uncertainty) a fair value price of $60.51.
The market sectors were mixed Thursday with a majority of the sectors trending up. Information Technology saw the biggest increase of the day (2.47%), while Financials saw the biggest drop (-0.30%). Information Technology has seen the biggest year-to-date gain at 21.08%.
Information Technology saw the biggest turnaround from its 5-day performance of 4.06%, as it went up 2.47%. Financials saw a turn around from its 5-day performance of -1.51% trading down -0.30%.
- Information Technology went up with a 2.47% change.
- Real Estate went up with a 1.79% change.
- Consumer Discretionary went up with a 1.32% change.
- Consumer Staples went up with a 1.19% change.
- Utilities went up with a 1.05% change.
- Materials went up with a 1.04% change.
- Industrials went up with a 0.95% change.
- Communication Services went up with a 0.89% change.
- Energy went up with a 0.69% change.
- Healthcare went up with a 0.35% change.
- Financials went down with a -0.30% change.
Glaukos Corp Info
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. The company’s product pipeline includes iStent Inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry; iStent Supra suprachoroidal micro-bypass stent, which is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. Its product pipeline also consists of iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure; and iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma. The company markets its products through direct sales force in the United States and internationally, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation has a collaboration agreement with D. Western Therapeutics Institute for the development of novel intraocular products for the treatment of glaucoma. The company was founded in 1998 and is headquartered in San Clemente, California.
All amounts in USD unless otherwise indicated
Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.